Key Insights

Highlights

Success Rate

74% trial completion

Published Results

286 trials with published results (20%)

Research Maturity

527 completed trials (36% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

12.7%

186 terminated out of 1464 trials

Success Rate

73.9%

-12.6% vs benchmark

Late-Stage Pipeline

8%

123 trials in Phase 3/4

Results Transparency

54%

286 of 527 completed with results

Key Signals

286 with results74% success186 terminated

Data Visualizations

Phase Distribution

1,278Total
Not Applicable (108)
Early P 1 (23)
P 1 (586)
P 2 (438)
P 3 (106)
P 4 (17)

Trial Status

Completed527
Recruiting290
Unknown193
Terminated186
Active Not Recruiting122
Not Yet Recruiting64

Trial Success Rate

73.9%

Benchmark: 86.5%

Based on 527 completed trials

Clinical Trials (1464)

Showing 20 of 20 trials
NCT07581002Phase 2RecruitingPrimary

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

NCT06514261Phase 1SuspendedPrimary

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

NCT07306832Phase 1RecruitingPrimary

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT06672146Phase 2RecruitingPrimary

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

NCT05554406Phase 2RecruitingPrimary

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

NCT05564390Phase 2RecruitingPrimary

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT06232655Phase 2Active Not RecruitingPrimary

Cladribine Venetoclax in Monocytic AML

NCT07295951Phase 1Recruiting

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

NCT06317649Phase 2RecruitingPrimary

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT06287944Phase 1Recruiting

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

NCT06021600Phase 1Terminated

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

NCT07737769Phase 1Not Yet RecruitingPrimary

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT07548710Phase 2RecruitingPrimary

Study of SA+X in the Treatment of Newly Diagnosed AML

NCT05457556Phase 3Active Not Recruiting

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

NCT06529731Phase 2RecruitingPrimary

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

NCT06616636Phase 1Recruiting

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

NCT04293562Phase 3RecruitingPrimary

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT07735208Phase 2Not Yet RecruitingPrimary

Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia

NCT06034470Phase 1Active Not RecruitingPrimary

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

NCT04093570Phase 2Enrolling By InvitationPrimary

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Scroll to load more

Research Network

Activity Timeline